The British Journal
of Cardiology
This website is intended for healthcare professionals only
VIEW TAGS
Articles tagged ‘type 2 diabetes’
November 2009
Br J Cardiol 2009;16:269-71
CHD risk is being overestimated in diabetes
The Framingham and UKPDS (United Kingdom Prospective Diabetes Study) risk equations overestimate the probability of cardiovascular events in people with type 2 diabetes, according to...
July 2009
Br J Cardiol 2009;16:163-6
New NICE guidelines on new treatments for type 2 diabetes
The National Institute for Health and Clinical Excellence (NICE) has issued a new guidance on the use of several newer agents for blood glucose control...
November 2008
Br J Cardiol 2008;15:301
News from the EASD
This year’s European Association for the Study of Diabetes meeting took place in Rome, Italy. Rhonda Siddall reports on the highlights of the meeting, which...
January 2007
Br J Cardiol 2007;14:57-60
‘Tidal wave’ of obesity and type 2 diabetes predicted to dominate CVD practice
The management of the ‘tidal wave’ of obesity and type 2 diabetes that is expected to hit the UK over the next 10 years was...
September 2006
Br J Cardiol 2006;13:347-50
Should cardiologists be interested in albuminuria?
Excretion of excess urinary albumin is a marker of generalised endothelial dysfunction and both progressive renal disease and cardiovascular events in those with and without...
March 2006
Br J Cardiol 2006;13:113-20
A new therapeutic target: the CB1 receptors of the endocannabinoid system and visceral fat
A constant abundance of food and a sedentary lifestyle has led to an increasing prevalence of obesity in the United Kingdom. This has resulted in...
January 2006
Br J Cardiol 2006;13:66-70
Heart disease prevention – what place for the glitazones?
This paper considers the role for glitazones in the treatment of type 2 diabetes following publication of the PROactive study, the first major outcome study...
March 2004
Br J Cardiol 2004;11:138-43
Will prevention of type 2 diabetes reduce the future burden of cardiovascular disease? The evidence base today
The prevalence of type 2 diabetes is set to double over the next 25 years, leading to substantial morbidity and mortality, particularly from macrovascular diabetic...
March 2004
Br J Cardiol 2004;11:129-36
Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine
Recent trials have broadened the evidence base for statin use. It has now been documented that these drugs are effective agents not only in the...
